Yuki Maruyama

Dr. Yuki Maruyama

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
YMYosuke Mitsui
Yosuke Mitsui
TSTakuya Sadahira
Takuya Sadahira
YMYuki Maruyama
Yuki Maruyama
RSRyota Sato
Ryota Sato
ARAcosta Gonzalez Herik Rodrigo
Acosta Gonzalez Herik Rodrigo
YNYasutomo Nasu
Yasutomo Nasu
Mitsui Y, et al. World J Mens Health. 2020 Jan;38:e60. https://doi.org/10.5534/wjmh.200036

6 May 2020 in LUTS: Lower Urinary Tract Symptoms
Verified
Journal Article
Closed access
PDF file
YMYosuke Mitsui
Yosuke Mitsui
TSTakuya Sadahira
Takuya Sadahira
TWToyohiko Watanabe
Toyohiko Watanabe
MAMotoo Araki
Motoo Araki
YMYuki Maruyama
Yuki Maruyama
YNYasutomo Nasu
Yasutomo Nasu

1 January 2021 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
KYKasumi Yoshinaga
Kasumi Yoshinaga
TSTakuya Sadahira
Takuya Sadahira
YMYuki Maruyama
Yuki Maruyama
YMYosuke Mitsui
Yosuke Mitsui
TITakehiro Iwata
Takehiro Iwata
YNYasutomo Nasu
Yasutomo Nasu
Yoshinaga K, et al. Investig Clin Urol. 2020 Aug;62:e1. https://doi.org/10.4111/icu.20200103

10 February 2022 in International Journal of Urology
Verified
Journal Article
Open access
PDF file
HAHerik Acosta
Herik Acosta
TSTakuya Sadahira
Takuya Sadahira
TSTakanori Sekito
Takanori Sekito
YMYuki Maruyama
Yuki Maruyama
TITakehiro Iwata
Takehiro Iwata
KWKoichiro Wada
Koichiro Wada
The development of several culture media and the availability to isolate and treat pathogens prior to a surgical procedure give us the ability to minimize treatment‐related complications, and ultimately results in better outcomes for patients and avoidance of unwanted post‐procedure inpatient admissions. In the last decade, an increasing incidence of multidrug‐resistant Escherichia coli, especially extended‐spectrum beta‐lactamase‐producing E. coli and fluoroquinolone‐resistant pathogens, has been reported. These resistant species frequently colonize the rectal flora and gain access to the systemic circulation via the rectal plexus following a prostate biopsy. The bacteria can eventually lead to life‐threatening complications, which is especially important in high‐risk patients with multiple co‐morbidities. Previously published studies have focused on the isolation of these pathogens with selective media before an invasive procedure and the potential benefits of incorporating the use of selective media as a mandatory pre‐operative step. This preventive measure will allow us to offer a tailored prophylactic treatment that benefits patients and reduces the economic burden for the hospital.

18 November 2024 in International Journal of Urology
Verified
Journal Article
Open access
MMMasao Mitsui
Masao Mitsui
TSTakuya Sadahira
Takuya Sadahira
NNNaoya Nagasaki
Naoya Nagasaki
YMYuki Maruyama
Yuki Maruyama
TSTakanori Sekito
Takanori Sekito
MAMotoo Araki
Motoo Araki
Objective: We evaluated the incidence of and risk factors for postoperative infections after robotic‐assisted radical prostatectomy (RARP) according to the type and duration of prophylactic antibiotic administration. Methods: A total of 1038 patients underwent RARP at our institution from 2010 to 2021; 1026 patients (201 in the cefazolin [CEZ] group and 825 in the ampicillin/sulbactam [ABPC/SBT] group) were analyzed, and 12 who used other antibiotics were excluded. The primary endpoint was the incidence of urinary tract infection (UTI), surgical site infection (SSI), and remote infection (RI). T‐tests, propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were performed. Multivariate logistic regression analysis was performed to evaluate the effect of type and duration of prophylactic antibiotic administration. Results: The incidence of UTI was 2.5% (5/201) in the CEZ group and 3.2% (26/825) in the ABPC/SBT group, with no significant difference between groups ( p = 0.622). The rates of SSI and RI were comparable between groups ( p = 0.680 and 0.906, respectively). Although the duration of antimicrobial therapy was longer in the ABPC/SBT group ( p < 0.001), there was no significant difference in the incidence of UTI/SSI/RI after PSM and IPTW (all p > 0.05). Multivariate logistic regression analysis showed that neither the type of antibiotic nor the duration of administration affected the incidence of UTI/SSI/RI. Conclusion: The risk of postoperative UTI/SSI/RI after RARP did not change with the type and duration of antimicrobial therapy.

1 October 2021 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
SWShogo Watari
Shogo Watari
MAMotoo Araki
Motoo Araki
JMJun Matsumoto
Jun Matsumoto
KYKasumi Yoshinaga
Kasumi Yoshinaga
TSTakanori Sekito
Takanori Sekito
YNYasutomo Nasu
Yasutomo Nasu